Population Pharmacogenetics of Ibero-Latinoamerican Populations (MESTIFAR 2014)

Sosa-Macías, Martha; Moya, Graciela; LLerena, Adrián; Ramírez, Rafael Robina; Terán, Enrique; Peñas-Lledó, Eva; Tarazona‐Santos, Eduardo; Galavíz-Hernández, Carlos; Céspedes-Garro, Carolina; Acosta, Hildaura

doi:10.2217/pgs.15.32

Cited by 9 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Through promoting summer schools, congresses, symposia, and workshops in PGx and PM, ESPT is perfectly managing educational activities [19]. The CEIBA-MESTIFAR project has focused mainly on determined genotyping CYPs genetic polymorphisms and the relationship between ancestry, pharmacogenetic genotypes and pharmacological phenotypes in population of different ethnic origin [5]. In this project, more than 6000 healthy volunteers have been evaluated, which constitutes the largest study of population pharmacogenomics developed to date worldwide.…”

Section: Pharmacogenetics and Personalized Therapeutics Networking Ementioning

confidence: 99%

“…This need has enhanced the creation of different multidisciplinary consortiums, such as the European Society of Pharmacogenomics and personalized Therapy (ESPT) [2,3]. The need of understanding intrinsic patients' aspects related to response to drugs resulted in organizations such as the Ibero-American network of Pharmacogenetics, RIBEF [4,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Progress in pharmacogenetics: consortiums and new strategies

Maroñas¹,

Latorre²,

Dopazo³

et al. 2016

Drug Metabolism and Personalized Therapy

Self Cite

View full text Add to dashboard Cite

Pharmacogenetics (PGx), as a field dedicated to achieving the goal of personalized medicine (PM), is devoted to the study of genes involved in inter-individual response to drugs. Due to its nature, PGx requires access to large samples; therefore, in order to progress, the formation of collaborative consortia seems to be crucial. Some examples of this collective effort are the European Society of Pharmacogenomics and personalized Therapy and the Ibero-American network of Pharmacogenetics. As an emerging field, one of the major challenges that PGx faces is translating their discoveries from research bench to bedside. The development of genomic high-throughput technologies is generating a revolution and offers the possibility of producing vast amounts of genome-wide single nucleotide polymorphisms for each patient. Moreover, there is a need of identifying and replicating associations of new biomarkers, and, in addition, a greater effort must be invested in developing regulatory organizations to accomplish a correct standardization. In this review, we outline the current progress in PGx using examples to highlight both the importance of polymorphisms and the research strategies for their detection. These concepts need to be applied together with a proper dissemination of knowledge to improve clinician and patient understanding, in a multidisciplinary team-based approach.

show abstract

Section: Pharmacogenetics and Personalized Therapeutics Networking Ementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Progress in pharmacogenetics: consortiums and new strategies

Maroñas¹,

Latorre²,

Dopazo³

et al. 2016

Drug Metabolism and Personalized Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs

Tuteja

2023

Curr Cardiovasc Risk Rep

View full text Add to dashboard Cite

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

Moya

Dorado

Ferreiro³

et al. 2016

Pharmacogenomics J

View full text Add to dashboard Cite

A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other North American Caucasians, which might be important to guide the prescription for CYP2D6 substrates in AJ communities around the world. This study was aimed to determine whether the high frequency of CYP2D6 gUMs described in AJ from USA was replicated in AJ from Argentina when compared with other multiethnic admixture Argentines (GA). The frequency of the most common allelic variants and of CYP2D6 gUMs (>2 active genes) and poor metabolizers (0 active genes, gPMs) was also compared among the studied Argentine populations. CYP2D6 genotyping was performed in 173 AJ and 246 GA DNA samples of unrelated donors from the metropolitan area of Buenos Aires. CYP2D6 alleles (*2, *3, *4, *5, *6, *10, *17, *35, *41 and multiple copies), genotypes and functional phenotype frequencies were determined. The frequencies of gUMs and gPMs in AJ from Argentina were 11.5% and 5.2%, respectively, whereas in GA, the frequencies of gUM and gPMs were 6.5% and 4.9%, respectively. Comparisons between AJ and GA showed that gUMs frequencies were twofold higher (P<0.05) in AJ than GA. CYP2D6*35 allele was more frequent in GA than AJ, whereas CYP2D6*41 and *1xN were more frequent in AJ than in GA (P<0.05). This study supports the previously reported high frequency of gUMs on another Ashkenazi population in New York. The present findings also support the interethnic variability of CYP2D6 genetic polymorphism in the overall Argentine population.

show abstract

Population Pharmacogenetics of Ibero-Latinoamerican Populations (MESTIFAR 2014)

Cited by 9 publications

References 20 publications

Progress in pharmacogenetics: consortiums and new strategies

Progress in pharmacogenetics: consortiums and new strategies

Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

Contact Info

Product

Resources

About